Bioton SA
WSE:BIO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
BIO's latest stock split occurred on Jan 14, 2014
The company executed a 1-for-100 stock split, meaning that for every 100 shares held, investors received 1 new share.
Before the split, BIO traded at 2 per share. Afterward, the share price was about 2.06.
The adjusted shares began trading on Jan 14, 2014. This was BIO's 2nd stock split, following the previous one in Jun 28, 2006.
Global
Stock Splits Monitor
| Date | Company | Split | Pre-Split Price | Post-Split Price | |
|---|---|---|---|---|---|
|
Apr 23, 2026
|
|
Red Sky Energy Ltd
ASX:ROG
|
5-for-4
x1.25
|
0.002 0.0016 AUD | 0.002 0.002 AUD |
|
Apr 23, 2026
|
J
|
Jiusheng Electric Co Ltd
SZSE:301082
|
1-for-1
x1
|
17.33 13.2508 CNY | 12.9 12.9 CNY |
|
Apr 23, 2026
|
S
|
Saudee Group Bhd
KLSE:SAUDEE
|
1-for-10
/10
|
0.01 0.1 MYR | 0.09 0.09 MYR |
|
Apr 23, 2026
|
|
Focus Technology Co Ltd
SZSE:002315
|
1-for-1
x1
|
44.3999 33.4538 CNY | 32 32 CNY |
|
Apr 22, 2026
|
S
|
Sharetronic Data Technology Co Ltd
SZSE:300857
|
1-for-1
x1
|
304.5701 217.2101 CNY | 260.76 260.76 CNY |
ROG
002315
Bioton SA
Glance View
BIOTON SA engages in the manufacture and production of medicine and pharmaceutical substances. The company is headquartered in Warsaw, Woj. Mazowieckie and currently employs 371 full-time employees. The company went IPO on 2005-03-16. The firm is engaged in research, development and wholesale trade of pharmaceutical and biotechnological products. The firm's portfolio consists of oral hypoglycemic drugs (metformin and glimepride) as well as recombinant human insulin in pharmaceutical substance form and for injections. Additionally, the Company provides advertising services. As of December 31, 2011, the Company formed a capital group and operated through its subsidiaries, including BIOTON TRADE Sp. z o.o., Mindar Holdings Ltd, Germonta Holdings Ltd, Tricel SA, SciGen Ltd and BioPartners Holdings AG, among others. On June 12, 2014, it sold a 50% stake in Copernicus Sp. z o.o.
